文献速递脑血管病

动脉内与静脉内替罗非班作为血管内取栓辅助治疗的效果比较

Intraarterial Versus Intravenous Tirofiban as an Adjunct to Endovascular Thrombectomy for Acute Ischemic Stroke.
PubMed 文献 · Stroke · 2020-09-16

本研究回顾性分析了503例在发病24小时内接受血管内取栓的大血管闭塞急性缺血性卒中患者,比较无替罗非班、动脉内替罗非班和静脉内替罗非班三组的疗效与安全性。倾向性评分匹配后,静脉内替罗非班与更高的再通率和3个月良好预后相关,而动脉内替罗非班与更高的症状性颅内出血和死亡风险相关。

要点

  • 静脉内替罗非班辅助取栓与更高的再通率和3个月良好预后相关。
  • 动脉内替罗非班与显著增加的症状性颅内出血和死亡风险相关。
  • 动脉内与静脉内替罗非班的疗效和安全性存在显著差异,需谨慎选择给药途径。

核心结论

  • 作为血管内取栓的辅助治疗,静脉内替罗非班与高再通率和良好预后相关,而动脉内替罗非班与高出血率和死亡率相关。

研究设计与样本

  • 回顾性研究纳入503例发病24小时内接受血管内取栓的大血管闭塞急性缺血性卒中患者,分为无替罗非班(n=354)、动脉内替罗非班(n=79)和静脉内替罗非班(n=70)三组,采用倾向性评分匹配后比较。

主要发现

  • 倾向性评分匹配后得到92个匹配三联组。
  • 与无替罗非班组相比,静脉内替罗非班组再通率显著增加(96.7% vs 64.1%,P<0.001),3个月良好预后率增加(69.5% vs 51.2%,P=0.034),3个月不良预后率降低(12.2% vs 41.4%,P<0.001)。
  • 静脉内替罗非班组与无替罗非班组在症状性颅内出血方面无显著差异(2.2% vs 0%,P=1.000)。
  • 与无替罗非班组相比,动脉内替罗非班组症状性颅内出血显著增加(19.1% vs 0%,P<0.001),院内死亡率增加(23.6% vs 0%,P<0.001),3个月死亡率增加(26.8% vs 11.1%,P=0.021)。
  • 动脉内替罗非班组与无替罗非班组再通率无显著差异(66.3% vs 64.1%,P=1.000)。

临床怎么用

  • 在血管内取栓辅助治疗中,静脉内替罗非班可能改善再通和预后,而动脉内替罗非班可能增加出血和死亡风险,临床决策时应考虑给药途径。

局限性

  • 本研究为回顾性研究,样本量有限,结果需前瞻性研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: This study aimed to evaluate the treatment effect of intraarterial versus intravenous tirofiban during endovascular thrombectomy in acute ischemic stroke. METHODS: This study retrospectively examined 503 patients with acute ischemic stroke with large vessel occlusion who received endovascular thrombectomy within 24 hours of stroke onset. Patients were divided into 3 groups: no tirofiban (n=354), intraarterial tirofiban (n=79), and intravenous tirofiban (n=70). The 3 groups were compared in terms of recanalization rate, symptomatic intracerebral hemorrhage, in-hospital death rate, 3-month death, and 3-month outcomes measured by modified Rankin Scale score (good clinical outcome of 0-2, poor outcome of 5-6). The comparison was statistically assessed by propensity score matching, followed by Freidman rank-sum test and pairwise Wilcoxon signed-rank test with Bonferroni correction. RESULTS: The propensity score matching resulted in 92 matched triplets. Compared with the no-tirofiban group, the intravenous tirofiban group showed significantly increased recanalization (96.7% versus 64.1%, P<0.001), an increased rate of 3-month good outcome (69.5% versus 51.2%, P=0.034), and a lower rate of 3-month poor outcome (12.2% versus 41.4%, P<0.001). There was no significant difference between the tirofiban intravenous and no-tirofiban groups in terms of symptomatic intracerebral hemorrhage (2.2% versus 0%, P=1.000). However, symptomatic intracerebral hemorrhage was significantly increased in the intraarterial-tirofiban group compared with the no-tirofiban group (19.1% versus 0%, P<0.001), with an increased rate of in-hospital death (23.6% versus 0% P<0.001), and increased rate of 3-month death (26.8% versus 11.1%, P=0.021). The intraarterial-tirofiban and no-tirofiban group showed no significant difference in recanalization rate (66.3% versus 64.1%, P=1.000). CONCLUSIONS: As an adjunct to endovascular thrombectomy, intravenous tirofiban is associated with high recanalization rate and good outcome, whereas intraarterial tirofiban is associated with high hemorrhagic rate and death rate.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Yang J, Wu Y, Gao X, et al. Intraarterial Versus Intravenous Tirofiban as an Adjunct to Endovascular Thrombectomy for Acute Ischemic Stroke. Stroke. 2020. PMID: 32933416. doi:10.1161/STROKEAHA.120.029994

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。